



REGENERATING NERVES DAMAGED OR DESTROYED BY NEUROPATHY

RH. Odell¹, P Carney².

¹Neuropathy & Pain Centers of America, Las Vegas, NV ; ²Neurosurgeon in private practice, Elkhart, IN

Objective

To show that EST/CET regenerates nerves damaged or destroyed by neuropathy

Background


Peripheral Neuropathy (PN) affects millions and has been described as a neurodegenerative disease which impairs regeneration of peripheral nerves. At this time we only treat symptoms with drugs. In the future, clinicians must find ways to regenerate nerves. Concepts called EST (Electronic Signal Treatment) and CET (Combined Electrochemical Treatment) have produced better results in treating painful peripheral neuropathy (PPN) than pharmacology.

We have shown that CET for neuropathy is twice as effective as medication and has essentially no side effects, as compared to at least 38% side effects reported with pregabalin. Patients have been able to eliminate reliance on walking aids. Epidermal nerve fiber density (ENFD) biopsies and A-delta NCS neurodiagnostic testing demonstrate objective proof reflecting the clinical success of CET. A Blue ribbon poster presentation at the American Academy of Pain Management by one of us (PMC) in Sept. 2014 validated the use of CET.

Materials and Methods


Forty-one adults with clinically documented PPN seen at three different clinics consented to receive an innovative technique called EST/CET. They all received CET/ EST delivered to each extremity twice a week for up to 25 treatments. Their highest numeric rating scale (NRS) during and at the end of treatment were obtained. ENFD biopsies were performed at 2 or 3 different sites before and 3 to 7 months after stopping treatment.

Anatomic Results - ENFD (nerve) growth



Nerve regrowth was shown at 43% of biopsy sites. A majority of patients showed nerve growth at 1 or more sites

Chart below shows that 25 patients had a >25% nerve growth, 5 patients had 1-25% growth, & 11 patients had no growth.





Clinical Results - Symptom Improvement

Table				
Test	# Pts	Pre CET	Post CET	% Change
VAS	41	7.5 (2-10)	1.9 (0-8)	75%

35 of 41 (85%) of patients reduced their pain by > 50%

Case Example: 0.0 nerves/mm to 3.4 nerves/mm (normal)

65 year old female with diabetic peripheral neuropathy - 16 CETs in 3 months
Pre CET: VAS = 9
Post CET: VAS = 2



Case Example: 0.0 nerves/mm to 3.4 nerves/mm (normal)

65 y/o male presented with idiopathic peripheral neuropathy -- 20 CETs in 6 months
Pre CET: VAS = 9
Post CET: VAS = 2



Conclusions

The anatomic pictures demonstrate that EST/CET regenerates epidermal nerves, improving numbness and possibly decreasing local peripheral deafferentation pain. Millions of patients suffering from neuropathic pain await an effective treatment that allows nerves to regenerate rather than just treating their symptoms. Treatments are virtually risk free. CET is well documented to be effective when used as a non-pharmacologic option to the current treatments of neuropathy, myofascial and central pain syndromes. We can now reclaim the art of medicine by healing, and not just papering over symptoms with drugs.

The Integrated Nerve Block: Electrical + Chemical; Poster Presentation to the 18th Annual International Spine Intervention Society Meeting, Las Vegas, NV, July 23 – 26, 2008

Poster presentation: Odell R, Carney P, Sorgnard R. The Combination Electrochemical Block in the Treatment of Peripheral Neuropathy: Preliminary Results; World Institute of Pain 6th World Congress, Miami, FL, February 2012

Poster presentation: Cernak C, Odell R, Marriott E, Silvani B; Combination Electrochemical Therapy (CET) to treat patients with diabetic neuropathy, American Society of Regional Anesthesia 35th Annual Meeting & Workshops, Toronto, CA, April 2010

Odell R, Sorgnard R. New Device Combines Electrical Currents and Local Anesthetic for Pain Management; Practical Pain Management (2011) 11 (5): 52-68

Cernak C, Marriott E, Martini J, Fleishman J, Silvani B, McDermott M. Electric Current and Local Anesthetic Combination Successfully Treats Pain Associated with Diabetic Neuropathy. Practical Pain Management (2012) 12 (3): 23-36

Odell R, Sorgnard R. Anti-Inflammatory Effects of Electronic Signal Treatment; Pain Physician (2008) 8 (6): 891-907

SLV and SLV-2, manufactured by Sanexas, GmbH, Germany, was utilized exclusively in this study

Levine T, Levine M, Hank N, Saperstein DS. Retrospective Assessment of the Usefulness of Skin Biopsies in the Evaluation and Management of Patients with Suspected Small Fiber Neuropathy. Neurology 2009; 72 (Suppl. 3):A56-57

Saperstein D, Levine T. Diagnosing Small Fiber Neuropathy Through the Use of Skin Biopsy; Practical Neurology, October 2009

Guyton & Hall Textbook of Medical Physiology 11th Ed. , 2006: 601

Cork RC, Saleem S, Hernandez L, Schuit T, Brandt S. Predicting nerve root pathology with voltage-actuated sensory nerve conduction threshold. The Internet Journal of Anesthesiology, (6:1), 2002.

Carney P; A-Delta nerve Conduction Study Benefits Patients with Spine Pain; Practical Pain Management (2012) 12 (5): 23-36

Hedgecock J. Description of Test Analysis, A-delta NCS device manual (1998-2012)

Shah J; New frontiers in the Pathophysiology of Myofascial Pain; The Pain Practitioner (2012) 22 (2):26- —

Perkins B, Olaleye D, Zinman B, Bri V. Simple Screening Tests for Peripheral Neuropathy in the Diabetes Clinic; Diabetes Care February 2001; 24 (2): 250-256

Ziegler D; Quantitative Sensory Testing (QST); Institute for Clinical Diabetology; German diabetes Center at Heinrich Heine University; 8/8/13; <http://www.fda.gov/downloads/Drugs/NewsEvents/UCM343132.pdf>

Sadosky A, Schaefer C, Mann R, Berstrom F, Bail R, Parsons B, Nalamachu S, Nieshoff E, Stacey B, Ansel A, Tuchman M; Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey; Diabetes Metab Syndr Obes. 2013;6:79-92

Vinik AI. Abstract #276. Presented at: the AACE Annual Scientific and Clinical Congress; May 3-5, 2013; Phoenix.